This week, dermatology experts are gathering in Paris, France, for the 6th Congress of Skin Inflammation and Psoriasis International Network to discuss advances in the treatment of inflammatory skin diseases. During the congress, researchers from the University of Verona in Verona, Italy, will report findings from a study in which patients were switched between 2 different biosimilar infliximab products during treatment of chronic plaque psoriasis.
This week, dermatology experts are gathering in Paris, France, for the 6th Congress of Skin Inflammation and Psoriasis International Network to discuss advances in the treatment of inflammatory skin diseases.
During the congress, researchers from the University of Verona in Verona, Italy, will report findings from a study in which patients were switched between 2 different biosimilar infliximab products during treatment of chronic plaque psoriasis.
In the study, 24 patients with psoriasis (12 of whom also had psoriatic arthritis) were switched from one infliximab biosimilar, CT-P13 (Inflectra, Remsima), to another, SB2 (Renflexis, Flixabi). The patients, who had a previous exposure to CT-P13 of 23.2 (± 7.51) months, were then followed for 6 months after switching. Psoriasis Area and Severity Index (PASI) scores were measured at the time of the switch and at months 2, 4, and 6.
The investigators found that PASI scores at each measurement were substantially unchanged; mean scores at the time of the switch and at months 2, 4, and 6 were 0.67 (±1.38), 0.76 (±1.08), 0.71 (±0.93), and 0.42 (±0.62), respectively.
In terms of adverse events (AEs), in total, 2 infusion-related reactions were observed, and 2 upper respiratory bacterial infections were observed.
Despite the fact that the sample size and length of follow-up were limited, the switch between the biosimilars, say the researchers, was not associated with a statistically significant change in PASI score or with increased AEs.
These findings mark a contribution to the literature on such switches. Switching among multiple products is increasingly common in countries where single-winner tenders for biosimilars are undertaken and in which patients may be asked to transition among products regularly based on the winner of the tender.
However, fewer data are available concerning switches among multiple biosimilars of the same reference than between 1 biosimilar and its reference, and these data may provide reassurance to prescribers who have concerns about the safety and efficacy of switching among multiple biosimilars.
Reference
Gisondi P, Virga C, Girolomoni G. Cross-switch from CT-P13 to sb2 infliximab biosimilars in patients with chronic plaque psoriasis. Presented at: 6th Congress of Skin Inflammation and Psoriasis International Network; April 25-27, 2019; Paris, France. Abstract P049.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.